Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
The University of Texas, Galveston |
---|---|
Information provided by: | The University of Texas, Galveston |
ClinicalTrials.gov Identifier: | NCT00582400 |
The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative toxicities of this treatment, and to measure the response to treatment and the patterns of failure and survival.
The primary response measurements will be the achievement of an objective tumor response, response duration and progression-free survival
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Hepatocellular |
Drug: arsenic trioxide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment |
Official Title: | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver |
Estimated Enrollment: | 30 |
Study Start Date: | September 2004 |
Estimated Study Completion Date: | August 2012 |
Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
I: Experimental |
Drug: arsenic trioxide
Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications. The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution. |
Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed malignancies in some regions of the world, particularly Africa and the Asian portion of the Pacific rim. However, it is an uncommon malignancy in the United States, with less than 14,000 cases diagnosed annually. Malignancies of the gallbladder and biliary tree are also uncommon. As with most solid tumors, unless either neoplasm can be resected completely, the prognosis is grim. A variety of agents have been utilized in the therapy of HCC and cholangiocarcinoma, both as single agents and in combination regimens. However, despite response rates which exceed 50% when hepatic arterial therapy is utilized for HCC, response rates for cholangiocarcinoma and for systemic treatment of HCC are considerably lower. Long term survival remains uncommon. For this reason, new therapeutic approaches must be evaluated.
Trisenox (arsenic trioxide) is a newly-approved pharmaceutical grade arsenic compound antineoplastic agent which has demonstrated clear activity in anthracycline- and all-trans retinoic acid-resistant acute promyelocytic leukemia. Trisenox also has US Compendium listing for acute leukemia, chronic myelogenous and lymphocytic leukemias, myelodysplasia, multiple myeloma, and hepatocellular carcinoma (HCC). Similar to the taxanes and vinca alkaloids, Trisenox appears to interfere with microtubule function, which triggers cell differentiation, and induces programmed death, or apoptosis. The mechanism of this is unclear, but appears to involve activation of caspases and the down-regulation of the BCL-2 oncogene. Trisenox also interfere with the function of NF-kappaB, leading to inhibition of cellular proliferative signals, apoptosis, and inhibition of tumor angiogenesis.
Trisenox was shown to be effective in a pivotal trial consisting of 40 subjects, ages 5 to 72, at a nine-institution multi-center trial led by Memorial Sloan-Kettering Cancer Center. With Trisenox, 70% of the subjects achieved a complete remission, and 79% of the complete responders achieved a molecular remission as measured by reverse transcriptase-polymerase chain reaction (RT-PCR). Complete remission was achieved on average within two months after initiation of Trisenox. Sixty-eight percent of subjects who achieved complete remission were still alive and 58% were disease free, at a median follow-up time of 16 months.
To date, an optimal dose and schedule of Trisenox has not yet been defined. This agent has been administered on daily, twice a week, and weekly doses. As there is no evidence that one regimen is clearly superior to any other, for the sake of convenience, participants on this trial will receive Trisenox on the weekly schedule.
Administration of chemotherapy on a weekly schedule is commonly utilized across a broad spectrum of regimens and tumor types. On this trial, subjects will receive a dose of intravenous Trisenox 0.35 mg/kg on days 1, 8, 15, and 22 over two hours. Each cycle will be 28 days in length. Subjects will receive two treatment cycles (8 weeks) and then undergo objective radiographic tumor assessments. On this study, subjects may receive up to a maximum of 12 such treatment cycles. As the outlook for subjects with advanced primary liver cancer is so poor, new regimens and treatment strategies must be evaluated.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Linda Valencia-Stephens, RN | 4097728714 | lsvalenc@utmb.edu |
Contact: Lisa Hernandez Garcia | 4097728714 | lghernan@utmb.edu |
United States, Texas | |
University of Texas Medical Branch at Galveston | Recruiting |
Galveston, Texas, United States, 77555 |
Principal Investigator: | Avi B. Markowitz, MD | University of Texas Medical Branch at Galveston |
Responsible Party: | University of Texas Medical Branch at Galveston ( Avi B. Markowitz, MD ) |
Study ID Numbers: | 04-267, PI-Initiated |
Study First Received: | December 19, 2007 |
Last Updated: | February 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00582400 History of Changes |
Health Authority: | United States: Institutional Review Board |
livers, hepatocellular carcinoma (HCC) |
Liver Neoplasms Liver Diseases Digestive System Diseases Digestive System Neoplasms Carcinoma, Hepatocellular Arsenic trioxide |
Gastrointestinal Neoplasms Hepatocellular Carcinoma Adenocarcinoma Neoplasms, Glandular and Epithelial Carcinoma |
Liver Diseases Neoplasms by Histologic Type Digestive System Neoplasms Carcinoma, Hepatocellular Antineoplastic Agents Arsenic trioxide Pharmacologic Actions Carcinoma |
Liver Neoplasms Neoplasms Neoplasms by Site Digestive System Diseases Therapeutic Uses Adenocarcinoma Neoplasms, Glandular and Epithelial |